HK1080768A1 - Use of epothilone derivatives for the treatment ofhyperparathyroidism - Google Patents

Use of epothilone derivatives for the treatment ofhyperparathyroidism

Info

Publication number
HK1080768A1
HK1080768A1 HK06100631A HK06100631A HK1080768A1 HK 1080768 A1 HK1080768 A1 HK 1080768A1 HK 06100631 A HK06100631 A HK 06100631A HK 06100631 A HK06100631 A HK 06100631A HK 1080768 A1 HK1080768 A1 HK 1080768A1
Authority
HK
Hong Kong
Prior art keywords
ofhyperparathyroidism
treatment
epothilone derivatives
animal
epothilone
Prior art date
Application number
HK06100631A
Other languages
English (en)
Inventor
Eugene A Woltering
Original Assignee
Univ Louisiana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisiana State filed Critical Univ Louisiana State
Publication of HK1080768A1 publication Critical patent/HK1080768A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK06100631A 2002-10-15 2006-01-13 Use of epothilone derivatives for the treatment ofhyperparathyroidism HK1080768A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41859202P 2002-10-15 2002-10-15
PCT/IB2003/004514 WO2004035050A1 (fr) 2002-10-15 2003-10-13 Utilisation de derives d'epothilone pour le traitement de l'hyperparathyroidie

Publications (1)

Publication Number Publication Date
HK1080768A1 true HK1080768A1 (en) 2006-05-04

Family

ID=32107949

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06100631A HK1080768A1 (en) 2002-10-15 2006-01-13 Use of epothilone derivatives for the treatment ofhyperparathyroidism

Country Status (16)

Country Link
US (2) US20060142354A1 (fr)
EP (1) EP1553938B1 (fr)
JP (1) JP4672368B2 (fr)
CN (1) CN1297269C (fr)
AT (1) ATE350034T1 (fr)
AU (1) AU2003267751A1 (fr)
BR (1) BR0315293A (fr)
CA (1) CA2501717C (fr)
CY (1) CY1106385T1 (fr)
DE (1) DE60310975T2 (fr)
DK (1) DK1553938T3 (fr)
ES (1) ES2279139T3 (fr)
HK (1) HK1080768A1 (fr)
PT (1) PT1553938E (fr)
SI (1) SI1553938T1 (fr)
WO (1) WO2004035050A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1767535T3 (da) 2002-08-23 2010-04-12 Sloan Kettering Inst Cancer Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502664T1 (de) * 1993-07-19 2011-04-15 Angiotech Pharm Inc Herstellungsmethode eines stents mit anti- angiogener zusammensetzung
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
ID26549A (id) * 1998-02-05 2001-01-18 Novartis Ag Komposisi-komposisi epotilon
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones

Also Published As

Publication number Publication date
ATE350034T1 (de) 2007-01-15
CA2501717A1 (fr) 2004-04-29
AU2003267751A1 (en) 2004-05-04
DE60310975D1 (de) 2007-02-15
EP1553938B1 (fr) 2007-01-03
CY1106385T1 (el) 2011-10-12
SI1553938T1 (sl) 2007-06-30
JP4672368B2 (ja) 2011-04-20
JP2006504751A (ja) 2006-02-09
US20110152329A1 (en) 2011-06-23
ES2279139T3 (es) 2007-08-16
DK1553938T3 (da) 2007-03-26
BR0315293A (pt) 2005-08-30
CN1297269C (zh) 2007-01-31
CN1703217A (zh) 2005-11-30
DE60310975T2 (de) 2007-07-12
CA2501717C (fr) 2012-09-18
PT1553938E (pt) 2007-03-30
WO2004035050A1 (fr) 2004-04-29
EP1553938A1 (fr) 2005-07-20
US20060142354A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
DE60329001D1 (en) 8-hydroxychinolinderivate
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
MY138352A (en) Benzothiazole derivatives
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
WO2006067165A3 (fr) Medicaments pour le traitement ou la prevention de maladies fibrotiques
GB0225475D0 (en) Therapeutic agents
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
TW200420549A (en) Thiazole derivatives
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2004014906A3 (fr) Agents topoisomerase nitro et amino substitues
WO2007047893A3 (fr) Utilisation de dasatinib dans le traitement de metastase osseuse
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
IL156140A0 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
ATE435853T1 (de) Prostaglandinanaloga
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
HRP20050281A2 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
WO2004035031A3 (fr) Traitement du melanome uveal
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131013